INTELLIGENT BIO SOLUTIONS INC.
INBSNasdaqHealthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $3.1M | $3.1M | $1.3M | $437,146 | $2.0M | $188,744 |
| Operating income | −$10.6M | −$10.3M | −$12.6M | −$8.3M | −$5.6M | −$2.9M |
| Net income | −$10.6M | −$10.2M | −$10.6M | −$8.3M | −$7.0M | −$3.2M |
| Total assets | $8.2M | $13.8M | $10.4M | $12.4M | $21.9M | $2.5M |
| Total liabilities | $5.4M | $5.6M | $6.7M | $5.8M | $6.9M | $7.7M |
| Equity | $3.0M | $8.3M | $3.8M | $6.6M | $15.1M | −$5.2M |
| EPS (diluted) | $-2.00 | $-6.38 | $-127.00 | $-11.33 | $-0.68 | — |
| Shares out. | 9.0M | 4.2M | 2.3M | 14.9M | 14.9M | 8.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −348.7%
- Net margin
- −346.2%
- Return on equity
- −352.7%
- Return on assets
- −128.1%
- Return on capital (ROCE)
- −367.2%
- Liabilities / assets
- 65.9%
- Debt / equity
- 1.81×
- Book value / share
- $0.33
- Revenue growth (YoY)
- −1.9%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -33.77distress
- Accruals / assets
- −10.8%clean
- Beneish M-Score
- -2.63normal
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 4 warning● 1 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Armistice Capital, LlcPassive (13G)May 15, 2026
- Alyeska Investment Group, L.P.Passive (13G)Nov 14, 2025
- Bigger Capital Fund L PPassive (13G)Feb 4, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Boyages Steven ConstantineDirector | Mar 18, 2026 | Grant | 5,000 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 149,005 | 1.0 | +172.7% |
| Apr 30, 2026 | 54,635 | 1.0 | +102.2% |
| Apr 15, 2026 | 27,026 | 1.0 | -39.3% |
| Mar 31, 2026 | 44,510 | 1.0 | +0.2% |
| Mar 13, 2026 | 44,416 | 1.0 | -53.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 14, 2026
- Regulation FD disclosure · Other material eventApr 20, 2026
- Director / officer change · Other material eventMar 23, 2026
- Regulation FD disclosureFeb 25, 2026
- Results of operationsFeb 12, 2026
- Results of operationsFeb 5, 2026
- Regulation FD disclosureJan 28, 2026
- Other material eventJan 8, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.